Chloropyramine is a competitive reversible H1 receptor antagonist that can be used in allergic conditions research, for example, conjunctivitis and bronchial asthma. Chloropyramine also shows anti-tumour activity in breast cancer [1] [2].

Chloropyramine at concentrations of 25 and 50 μM over periods of 24 and 48 hours has been shown to increase SASH1 expression and induce apoptosis in various breast cancer cell lines (T47D, MDA-MB-231, and BT-54). According to Western Blot analysis, enhanced SASH1 expression was observed after 24 hours at the given concentrations. Additionally, apoptosis was prominently induced after 48 hours of exposure to 50 μM Chloropyramine, as evidenced by apoptosis analysis.

Chloropyramine (i.p.; 10 mg/kg) effectively counteracts histamine-induced hypothermia in rats. Utilizing an animal model comprising rats [2], the study administered a dosage of 10 mg/kg through the intraperitoneal route. The outcome highlighted a significant reduction in hypothermia triggered by histamine.